Protocol Ledger

NCT05201079 · Phase III · COMPLETED

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

Interventional Phase III clinical trial protocol NCT05201079 sponsored by Mikrobiomik Healthcare Company S.L in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-29 Enrollment: 93 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05201079
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)93 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05201079
Protocol FieldVerified Registry Value
NCT IdentifierNCT05201079
Consolidated Lead SponsorMikrobiomik Healthcare Company S.L
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment93 participants (ACTUAL)
Registered Start Date2021-10-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05201079
Hospital Research SiteLocationSite Profile
Hospital Universitario Marqués de ValdecillaSantander, SpainOpen Hospital Dossier ->
Hospital General Universitario de AlicanteAlicante, SpainOpen Hospital Dossier ->
Hospital Clínic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI